Current status and implications of microRNAs in ovarian cancer diagnosis and therapy.
Current status and implications of microRNAs in ovarian cancer diagnosis and therapy.
复制标题
DOI：
10.1186/1757-2215-5-44
复制
发表时间：
2012-12-13
影响因子：
4
通讯作者：
Chauhan SC
中科院分区：
文献类型：
--
作者：
Zaman MS;Maher DM;Khan S;Jaggi M;Chauhan SC
卵巢癌是女性第五大常见癌症，导致的死亡人数比任何其他类型的女性生殖癌症都要多。目前，卵巢癌的治疗以手术和化疗相结合为主。虽然复发性卵巢癌对额外的化疗有反应，但每个周期后无进展间隔会变短，因为化疗耐药性会增加，直到疾病变得无法治愈。因此，迫切需要预后和预测标记物来帮助优化和个性化治疗，以改善卵巢癌的预后。越来越多的研究表明 microRNA 在卵巢癌进展和化疗耐药中发挥重要作用。 MicroRNA (miRNA) 是小型内源性非编码 RNA (~22bp)，在癌症中经常失调。通常，miRNA 参与重要的生物过程，包括发育、分化、细胞凋亡和增殖。两个 miRNA 家族，miR-200 和 let-7，在卵巢癌中经常失调，并与不良预后相关。两者都与上皮间质转化的调节有关，这是一种与肿瘤侵袭性、肿瘤侵袭和化疗耐药相关的细胞转变。此外，miRNA 还可能对改善癌症诊断产生影响。例如，miR-200家族、let-7家族、miR-21和miR-214可能在诊断测试中有用，以帮助早期发现卵巢癌。此外，使用多靶点O-修饰antagomirs (MTG-AMO)来抑制致癌miRNA和抑癌miRNA的miRNA替代疗法是基于miRNA的癌症治疗的重要工具。在这篇综述中，我们描述了 miRNA 在卵巢癌中发挥的作用的现状，并重点关注基于 microRNA 的治疗的可能性以及使用 microRNA 作为诊断工具。
Ovarian cancer is the fifth most common cancer among women and causes more deaths than any other type of female reproductive cancer. Currently, treatment of ovarian cancer is based on the combination of surgery and chemotherapy. While recurrent ovarian cancer responds to additional chemotherapy treatments, the progression-free interval becomes shorter after each cycle, as chemo-resistance increases until the disease becomes incurable. There is, therefore, a strong need for prognostic and predictive markers to help optimize and personalize treatment in order to improve the outcome of ovarian cancer. An increasing number of studies indicate an essential role for microRNAs in ovarian cancer progression and chemo-resistance. MicroRNAs (miRNAs) are small endogenous non-coding RNAs (~22bp) which are frequently dysregulated in cancer. Typically, miRNAs are involved in crucial biological processes, including development, differentiation, apoptosis and proliferation. Two families of miRNAs, miR-200 and let-7, are frequently dysregulated in ovarian cancer and have been associated with poor prognosis. Both have been implicated in the regulation of epithelial-to-mesenchymal transition, a cellular transition associated with tumor aggressiveness, tumor invasion and chemo-resistance. Moreover, miRNAs also have possible implications for improving cancer diagnosis; for example miR-200 family, let-7 family, miR-21 and miR-214 may be useful in diagnostic tests to help detect ovarian cancer at an early stage. Additionally, the use of multiple target O-modified antagomirs (MTG-AMO) to inhibit oncogenic miRNAs and miRNA replacement therapy for tumor suppressor miRNAs are essential tools for miRNA based cancer therapeutics. In this review we describe the current status of the role miRNAs play in ovarian cancer and focus on the possibilities of microRNA-based therapies and the use of microRNAs as diagnostic tools.
登录
查看更多内容
影响因子：
4.5
作者：
Cai, XZ;Hagedorn, CH;Cullen, BR
通讯作者：
Cullen, BR
影响因子：
11.8
作者：
Bialek, P;Kern, B;Karsenty, G
通讯作者：
Karsenty, G
影响因子：
10.3
作者：
du Bois, A;Lück, HJ;Pfisterer, J
通讯作者：
Pfisterer, J
影响因子：
11.2
作者：
Creighton CJ;Fountain MD;Yu Z;Nagaraja AK;Zhu H;Khan M;Olokpa E;Zariff A;Gunaratne PH;Matzuk MM;Anderson ML
通讯作者：
Anderson ML
影响因子：
4.7
作者：
Cittelly DM;Das PM;Salvo VA;Fonseca JP;Burow ME;Jones FE
通讯作者：
Jones FE